Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Biochemistry and Molecular Biology: Karni Rotem

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun 2020;11(1).

(2) Goldman-Wohl D, Greenfield C, Eisenberg-Loebl I, Denichenko P, Jbara A, Karni R, et al. Trophoblast lineage specific expression of the alternative splicing factor RBFOX2 suggests a role in placental development. Placenta 2020;100:142-149.

(3) Jubran MR, Rubinstein AM, Cojocari I, Adejumobi IA, Mogilevsky M, Tibi S, et al. Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading. Oncogenesis 2020;9(2).

(4) Denichenko P, Mogilevsky M, Cléry A, Welte T, Biran J, Shimshon O, et al. Specific inhibition of splicing factor activity by decoy RNA oligonucleotides. Nat Commun 2019;10(1).

(5) Kumar S, Sharife H, Kreisel T, Mogilevsky M, Bar-Lev L, Grunewald M, et al. Intra-Tumoral Metabolic Zonation and Resultant Phenotypic Diversification Are Dictated by Blood Vessel Proximity. Cell Metab 2019;30(1):201-211.e6.

(6) Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-Mediated Translation of TCF7L2. Cancer Res 2019;79(10):2480-2493.

(7) Neumann-Raizel H, Shilo A, Lev S, Mogilevsky M, Katz B, Shneor D, et al. 2-APB and CBD-mediated targeting of charged cytotoxic compounds into tumor cells suggests the involvement of TRPV2 channels. Front Pharmacol 2019;10.

(8) Mogilevsky M, Shimshon O, Kumar S, Mogilevsky A, Keshet E, Yavin E, et al. Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment. Nucleic Acids Res 2018;46(21):11396-11404.

(9) Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, et al. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer 2018;143(1):179-183.

(10) Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res 2018;78(10):2680-2690.

(11) Siegfried Z, Karni R. The role of alternative splicing in cancer drug resistance. Curr Opin Genet Dev 2018;48:16-21.

(12) Soudah T, Mogilevsky M, Karni R, Yavin E. CLIP6-PNA-Peptide Conjugates: Non-Endosomal Delivery of Splice Switching Oligonucleotides. Bioconjugate Chem 2017;28(12):3036-3042.

(13) Kozlovski I, Siegfried Z, Amar-Schwartz A, Karni R. The role of RNA alternative splicing in regulating cancer metabolism. Hum Genet 2017;136(9):1113-1127.

(14) Molho-Pessach V, Ramot Y, Mogilevsky M, Cohen-Daniel L, Eisenstein EM, Abu-Libdeh A, et al. Generalized verrucosis and abnormal T cell activation due to homozygous TAOK2 mutation. J Dermatol Sci 2017;87(2):123-129.

(15) Zahavi T, Maimon A, Kushnir T, Lange R, Berger E, Kornspan D, et al. Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function. Oncogene 2017;36(26):3729-3739.

(16) Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Res 2017;77(5):1155-1167.

(17) Schultz A-, Preussner M, Bunse M, Karni R, Heyd F. Activation-dependent TRAF3 exon 8 alternative splicing is controlled by CELF2 and hnRNP C binding to an upstream intronic element. Mol Cell Biol 2017;37(7).

(18) Malakar P, Chartarifsky L, Hija A, Leibowitz G, Glaser B, Dor Y, et al. Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival. Sci Rep 2016;6.

(19) Chen C-, Jan C-, Pi W-, Wang W-, Yang P-, Wang T-, et al. Heterogeneous nuclear ribonucleoproteins A1 and A2 modulate expression of Tid1 isoforms and EGFR signaling in non-small cell lung cancer. Oncotarget 2016;7(13):16760-16772.

(20) Jadaliha M, Zong X, Malakar P, Ray T, Singh DK, Freier SM, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget 2016;7(26):40418-40436.

(21) Danan-Gotthold M, Golan-Gerstl R, Eisenberg E, Meir K, Karni R, Levanon EY. Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res 2015;43(10):5130-5144.

(22) Shilo A, Siegfried Z, Karni R. The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. Mol Cell Oncol 2015;2(1).

(23) Lamm N, Maoz K, Bester AC, Im MM, Shewach DS, Karni R, et al. Folate levels modulate oncogene-induced replication stress and tumorigenicity. EMBO Mol Med 2015;7(9):1138-1152.

(24) Eshar S, Altenhofen L, Rabner A, Ross P, Fastman Y, Mandel-Gutfreund Y, et al. PfSR1 controls alternative splicing and steady-state RNA levels in Plasmodium falciparum through preferential recognition of specific RNA motifs. Mol Microbiol 2015;96(6):1283-1297.

(25) Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, et al. Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation. Cell Rep 2014;7(2):501-513.

(26) Shilo A, Hur VB, Denichenko P, Stein I, Pikarsky E, Rauch J, et al. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA 2014;20(4):505-515.

(27) Shimoni-Sebag A, Lebenthal-Loinger I, Zender L, Karni R. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. Carcinogenesis 2013;34(11):2498-2504.

(28) Siegfried Z, Bonomi S, Ghigna C, Karni R. Regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing in cancer. Int J Cell Biol 2013.

(29) Hochberg M, Gilead L, Markel G, Nemlich Y, Feiler Y, Enk CD, et al. Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes. Arch Dermatol Res 2013;305(6):519-528.

(30) Cohen-Eliav M, Golan-Gerstl R, Siegfried Z, Andersen CL, Thorsen K, Ørntoft TF, et al. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J Pathol 2013;229(4):630-639.

(31) Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, et al. S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1. Cell Rep 2013;3(1):103-115.

(32) Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis 2013;30(1):103-117.

(33) Li D, Yang H, Nan H, Liu P, Pang S, Zhao Q, et al. Identification of key regulatory pathways of myeloid differentiation using an mESC-based karyotypically normal cell model. Blood 2012;120(24):4712-4719.

(34) Eshar S, Allemand E, Sebag A, Glaser F, Muchardt C, Mandel-Gutfreund Y, et al. A novel Plasmodium falciparum SR protein is an alternative splicing factor required for the parasites' proliferation in human erythrocytes. Nucleic Acids Res 2012;40(19):9903-9916.

(35) Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012;19(2):220-228.

(36) Golan-Gerstl R, Cohen M, Shilo A, Suh S-, Bakàcs A, Coppola L, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011;71(13):4464-4472.

(37) Porat S, Weinberg-Corem N, Tornovsky-Babaey S, Schyr-Ben-Haroush R, Hija A, Stolovich-Rain M, et al. Control of pancreatic β cell regeneration by glucose metabolism. Cell Metab 2011;13(4):440-449.

(38) Thorsen K, Mansilla F, Schepeler T, Øster B, Rasmussen MH, Dyrskjøt L, et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell Proteomics 2011;10(1).

(39) Sinha R, Allemand E, Zhang Z, Karni R, Myers MP, Krainer AR. Arginine methylation controls the subcellular localization and functions of the oncoprotein splicing factor SF2/ASF. Mol Cell Biol 2010;30(11):2762-2774.

(40) Sun S, Zhang Z, Sinha R, Karni R, Krainer AR. SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol 2010;17(3):306-312.

(41) Karni R, Hippo Y, Lowe SW, Krainer AR. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A 2008;105(40):15323-15327.

(42) Gus Y, Karni R, Levitzki A. Subunit S5a of the 26S proteasome is regulated by antiapoptotic signals. FEBS J 2007;274(11):2815-2831.

(43) Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14(3):185-193.

(44) Karni R, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of β-catenin by enhancement of cap-dependent translation. Mol Cell Biol 2005;25(12):5031-5039.

(45) Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 2003;537(1-3):47-52.

(46) Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α expression under normoxia. J Biol Chem 2002;277(45):42919-42925.

(47) Karni R, Levitzki A. pp60(sSrc) is a caspase-3 substrate and is essential for the transformed phenotype of A431 cells. Mol Cell Biol Res Commun 2000;3(2):98-104.

(48) Karni R, Jove R, Levitzki A. Inhibition of pp60(c-Src) reduces Bcl-X(L) expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999;18(33):4654-4662.